Effects of food on the pharmacokinetics of ponatinib in healthy subjects.
What is known and objective Ponatinib is a potent oral tyrosine kinase inhibitor with activity against BCR- ABL, the primary driver of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia. This single-centre, single-dose, randomized, open-label, three-period c...
| Publicado en: | Journal of Clinical Pharmacy & Therapeutics Vol. 38; no. 6; pp. 440 - 445 |
|---|---|
| Autores principales: | , , , , |
| Formato: | research tables/charts randomized controlled trial Journal Article |
| Publicado: |
Wiley-Blackwell
Dec2013
|
| Acceso en línea: | Ver este registro en EBSCOhost |